Douglas W.P. Hay

Dr. Hay has more than 25 years of experience as a pharmaceutical executive in drug discovery in the biopharmaceutical industry, with a primary focus on respiratory and inflammatory diseases (including ETRAs for PAH). His last position was Vice President of the COPD Drug Discovery group within the Respiratory & Inflammation Centre for Excellence for Drug Discovery at GSK. Dr. Hay has identified more than 25 compounds for drug development with 3 approved, 1 NDA filed, and 1 compound completing Phase III clinical trials. Dr. Hay received his PhD in Physiology and Pharmacology from the University of Strathclyde in Glasgow, Scotland, UK.